[1] 郭琪, 袁明慧, 郭宇飞. 乳腺癌骨转移动物模型建立方法综述[J]. 中医临床研究, 2019, 11(7):144-146. DOI:10.3969/j.issn.1674-7860.2019.07.059. [2] 黄可婷, 金多晨, 党旖旎, 等. 基因工程小鼠胃癌模型的研究进展[J]. 胃肠病学, 2019, 24(11):683-687. DOI:10.3969/j.issn.1008-7125.2019.11.009. [3] 韩艳珍, 白明, 康乐, 等. 基于数据挖掘的宫颈癌动物模型应用分析[J]. 中药药理与临床, 2021:1-10. DOI:10.13412/j.cnki.zyyl.20210609.006. [4] 朱杨壮壮, 邹纯朴, 陈晓, 等. 小鼠肿瘤肺转移模型及其应用进展[J]. 中国实验方剂学杂志, 2019, 25(14):25-31. DOI:10.13422/j.cnki.syfjx.20190627. [5] 郑俊超, 费鹏飞, 冯宝约, 等. BALB/c小鼠结肠癌血性腹水模型的建立及机制探讨[J]. 世界中西医结合杂志, 2019, 14(4):513-515,526. DOI:10.13935/j.cnki.sjzx.190416. [6] 杨义, 景治涛. 人源化肿瘤组织异种移植的进展[J]. 解剖科学进展, 2019, 25(4):480-483. DOI:10.16695/j.cnki.1006-2947.2019.04.034. [7] OKADA S, VAETEEWOOTTACHARN K, KARIYA R.Establishment of a patient-derived tumor xenograft model and application for precision cancer medicine[J]. Chem Pharm Bull (Tokyo), 2018, 66(3):225-230. DOI:10.1248/cpb.c17-00789. [8] FLANAGAN S P.'Nude', a new hairless gene with pleiotropic effects in the mouse[J]. Genet Res, 1966, 8(3):295-309. DOI:10.1017/s0016672300010168. [9] GOTO T.Patient-derived tumor xenograft models: toward the establishment of precision cancer medicine[J]. J Pers Med, 2020, 10(3):64. DOI:10.3390/jpm10030064. [10] LAPIDOT T, FAJERMAN Y, KOLLET O.Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis[J]. J Mol Med (Berl), 1997, 75(9):664-673. DOI:10.1007/s001090050150. [11] ITO M, HIRAMATSU H, KOBAYASHI K, et al.NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells[J]. Blood, 2002, 100(9):3175-3182. DOI:10.1182/blood-2001-12-0207. [12] KOYANAGI Y, TANAKA Y, KIRA J, et al.Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain[J]. J Virol, 1997, 71(3):2417-2424. DOI:10.1128/jvi.71.3.2417-2424.1997. [13] PFLUMIO F, IZAC B, KATZ A, et al.Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immuno-deficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells[J]. Blood, 1996, 88(10):3731-3740. [14] MALETZKI C, BOCK S, FRUH P, et al.NSG mice as hosts for oncological precision medicine[J]. Lab Invest, 2020, 100(1):27-37. DOI:10.1038/s41374-019-0298-6. [15] UEDA T, YOSHINO H, KOBAYASHI K, et al.Hematopoietic repopulating ability of cord blood CD34+ cells in NOD/Shi-scid mice[J]. Stem Cells, 2000, 18(3):204-213. DOI:10.1634/stemcells.18-3-204. [16] TENTLER J J, TAN A C, WEEKES C D, et al.Patient-derived tumour xenografts as models for oncology drug development[J]. Nat Rev Clin Oncol, 2012, 9(6):338-350. DOI:10.1038/nrclinonc.2012.61. [17] ZHOU Q, FACCIPONTE J, JIN M, et al.Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies[J]. Cancer Lett, 2014, 344(1):13-19. DOI:10.1016/j.canlet.2013.10.015. [18] JACKSON S E, CHESTER J D.Personalised cancer medicine[J]. Int J Cancer, 2015, 137(2):262-266. DOI:10.1002/ijc.28940. [19] JANIAUD P, SERGHIOU S, IOANNIDIS J P A. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology[J]. Cancer Treat Rev, 2019, 73:20-30. DOI:10.1016/j.ctrv.2018.12.003. [20] GOLEBIEWSKA A, HAU A C, OUDIN A, et al.Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology[J]. Acta Neuropathol, 2020, 140(6):919-949. DOI:10.1007/s00401-020-02226-7. [21] WISE H C, SOLIT D B.Precision oncology: three small steps forward[J]. Cancer Cell, 2019, 35(6):825-826. DOI:10.1016/j.ccell.2019.05.009. [22] LIN S Y, CHANG HSU Y, PENG Y H, et al.Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer[J]. J Med Chem, 2019, 62(22):10108-10123. DOI:10.1021/acs.jmedchem.9b00722. [23] HIDALGO M, AMANT F, BIANKIN A V, et al.Patient-derived xenograft models: an emerging platform for translational cancer research[J]. Cancer Discov, 2014, 4(9):998-1013. DOI:10.1158/2159-8290.cd-14-0001. [24] STEBBING J, PAZ K, SCHWARTZ GK, et al.Patient-derived xenografts for individualized care in advanced sarcoma[J]. Cancer, 2014, 120(22):3588. [25] YARLA N S, MADKA V, PATHURI G, et al.Molecular targets in precision chemoprevention of colorectal cancer: an update from pre-clinical to clinical trials[J]. Int J Mol Sci, 2020, 21(24):9609. DOI:10.3390/ijms21249609. [26] COLLINS D C, SUNDAR R, LIM J S J, et al. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics[J]. Trends Pharmacol Sci, 2017, 38(1):25-40. DOI:10.1016/j.tips.2016.10.012. [27] CHO S Y, KANG W, HAN J Y, et al.An integrative approach to precision cancer medicine using patient-derived xenografts[J]. Mol Cells, 2016, 39(2):77-86. DOI:10.14348/molcells.2016.2350. [28] WITKIEWICZ A K, BALAJI U, ESLINGER C, et al.Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer[J]. Cell Rep, 2016, 16(7):2017-2031. DOI:10.1016/j.celrep.2016.07.023. [29] GONÇALVES A, BERTUCCI F, GUILLE A, et al. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study[J]. Oncotarget, 2016, 7(48):79428-79441. DOI:10.18632/oncotarget.12714. [30] ERRIQUEZ J, OLIVERO M, MITTICA G, et al.Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer[J]. Oncotarget, 2016, 7(18):26181-26191. DOI:10.18632/oncotarget.8325. [31] FRANCIS O L, MILFORD T A M, BELDIMAN C, et al. Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia[J]. J Investig Med, 2016, 64(3):740-744. DOI:10.1136/jim-2016-000076. [32] SIVANAND S, PEÑA-LLOPIS S, ZHAO H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma[J]. Sci Transl Med, 2012, 4(137):137ra75. DOI:10.1126/scitranslmed.3003643. [33] BERTOTTI A, MIGLIARDI G, GALIMI F, et al.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J]. Cancer Discov, 2011, 1(6):508-523. DOI:10.1158/2159-8290.cd-11-0109. [34] MIGLIARDI G, SASSI F, TORTI D, et al.Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas[J]. Clin Cancer Res, 2012, 18(9):2515-2525. DOI:10.1158/1078-0432.ccr-11-2683. [35] SEBASTIANI V, RICCI F, RUBIO-VIQUIERA B, et al.Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival[J]. Clin Cancer Res, 2006, 12(8):2492-2497. DOI:10.1158/1078-0432.ccr-05-2655. [36] DAS THAKUR M, SALANGSANG F, LANDMAN A S, et al.Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance[J]. Nature, 2013, 494(7436):251-255. DOI:10.1038/nature11814. [37] KORTMANN U, MCALPINE J N, XUE H, et al.Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts[J]. Clin Cancer Res, 2011, 17(4):783-791. DOI:10.1158/1078-0432.ccr-10-1382. [38] SCOTT C L, BECKER M A, HALUSKA P, et al.Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment[J]. Front Oncol, 2013, 3:295. DOI:10.3389/fonc.2013.00295. [39] GELMON K A, TISCHKOWITZ M, MACKAY H, et al.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study[J]. Lancet Oncol, 2011, 12(9):852-861. DOI:10.1016/s1470-2045(11)70214-5. [40] Fiebig HH, Schuchhardt C, Henss H, et al. Comparison of tumor response in nude mice and in the patients[J]. Behring Inst Mitt, 1984, 74:343-52. PMID: 6477362. [41] MATTERN J, BAK M, HAHN E W, et al.Human tumor xenografts as model for drug testing[J]. Cancer Metastasis Rev, 1988, 7(3):263-284. DOI:10.1007/bf00047755. [42] NÉMATI F, SASTRE-GARAU X, LAURENT C, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors[J]. Clin Cancer Res, 2010, 16(8):2352-2362. DOI:10.1158/1078-0432.CCR-09-3066. [43] PETERSON J K, HOUGHTON P J.Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development[J]. Eur J Cancer, 2004, 40(6):837-844. DOI:10.1016/j.ejca.2004.01.003. [44] WONG H, CHOO E F, ALICKE B, et al.Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response[J]. Clin Cancer Res, 2012, 18(14):3846-3855. DOI:10.1158/1078-0432.ccr-12-0738. [45] OKADA S, VAETEEWOOTTACHARN K, KARIYA R.Establishment of a patient-derived tumor xenograft model and application for precision cancer medicine[J]. Chem Pharm Bull (Tokyo), 2018, 66(3):225-230. DOI:10.1248/cpb.c17-00789. [46] MORTON C L, HOUGHTON P J.Establishment of human tumor xenografts in immunodeficient mice[J]. Nat Protoc, 2007, 2(2):247-250. DOI:10.1038/nprot.2007.25. [47] SEGRE J A, NEMHAUSER J L, TAYLOR B A, et al.Positional cloning of the nude locus: genetic, physical, and transcription maps of the region and mutations in the mouse and rat[J]. Genomics, 1995, 28(3):549-559. DOI:10.1006/geno.1995.1187. [48] JHAPPAN C, MORSE H C, FLEISCHMANN R D, et al.DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus[J]. Nat Genet, 1997, 17(4):483-486. DOI:10.1038/ng1297-483. [49] LAROCHELLE A, VORMOOR J, HANENBERG H, et al.Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy[J]. Nat Med, 1996, 2(12):1329-1337. DOI:10.1038/nm1296-1329. [50] SHULTZ L D, GOODWIN N, ISHIKAWA F, et al.Human cancer growth and therapy in immunodeficient mouse models[J]. Cold Spring Harb Protoc, 2014, 2014(7):694-708. DOI:10.1101/pdb.top073585. [51] ZHANG X, CLAERHOUT S, PRAT A, et al.A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models[J]. Cancer Res, 2013, 73(15):4885-4897. DOI:10.1158/0008-5472.can-12-4081. [52] HOFFMAN R M.Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts[J]. Nat Rev Cancer, 2015, 15(8):451-452. DOI:10.1038/nrc3972. [53] BYRNE A T, ALFÉREZ D G, AMANT F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts[J]. Nat Rev Cancer, 2017, 17(4):254-268. DOI:10.1038/nrc.2016.140. [54] 卓莹, 吴一龙, 郭爱林, 等. 荷人肺癌小鼠皮下移植瘤模型的建立及其生物学特性初探[J]. 中国肺癌杂志, 2010, 13(6):568-574. [55] 吴君正, 汤骥骜, 李汉贤. rhGH对人直肠癌小鼠肾包膜下移植瘤生长的影响[J]. 中国热带医学, 2007, 7(6):870-871,880. [56] OKADA S, GOTO H, YOTSUMOTO M.Current status of treatment for primary effusion lymphoma[J]. Intractable Rare Dis Res, 2014, 3(3):65-74. DOI:10.5582/irdr.2014.01010. [57] SHOEMAKER R H.The NCI60 human tumour cell line anticancer drug screen[J]. Nat Rev Cancer, 2006, 6(10):813-823. DOI:10.1038/nrc1951. [58] GAO H, KORN J M, FERRETTI S, et al.High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11):1318-1325. DOI:10.1038/nm.3954. [59] SAITO Y, ELLEGAST J M, RAFIEI A, et al.Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice[J]. Blood, 2016, 128(14):1829-1833. DOI:10.1182/blood-2015-10-676452. |